Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2018, Article ID 4673061, 7 pages
https://doi.org/10.1155/2018/4673061
Research Article

Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease’s Statin Therapy in Men

1Department of Physiology, Faculty of Natural Sciences and Mathematics, “Ss. Cyril and Methodius” University, Skopje, Macedonia
2Department of Abdominal Surgery, Faculty of Medicine, “Ss. Cyril and Methodius” University, Skopje, Macedonia
3Department of Radiology and Physical Therapy and Department of Internal Diseases in Ruminants, Faculty of Veterinary Medicine, “Ss. Cyril and Methodius” University, Skopje, Macedonia

Correspondence should be addressed to Nikola Hadzi-Petrushev; km.miku.fmp@alokin

Received 22 January 2018; Accepted 18 April 2018; Published 17 May 2018

Academic Editor: Robert Gogal

Copyright © 2018 Nikola Hadzi-Petrushev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Rolo, J. S. Teodoro, and C. M. Palmeira, “Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis,” Free Radical Biology and Medicine, vol. 52, no. 1, pp. 59–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. P. Levene and R. D. Goldin, “The epidemiology, pathogenesis and histopathology of fatty liver disease,” Histopathology, vol. 61, no. 2, pp. 141–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Zimmermann, R. Anty, J. Tordjman et al., “C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients,” Journal of Hepatology, vol. 55, no. 3, pp. 660–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Halliwell, “Free radicals, antioxidants and human disease,” The Lancet, vol. 344, no. 8924, pp. 721–724, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Baskol, M. Baskol, and D. Kocer, “Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis,” Clinical Biochemistry, vol. 40, no. 11, pp. 776–780, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. M. Comar and R. K. Sterling, “Review article: drug therapy for non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 2, pp. 207–215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Angulo and K. D. Lindr, “Treatment of non-alcoholic fatty liver: present and emerging therapies,” Seminars in Liver Disease, vol. 21, no. 1, pp. 81–88, 2001. View at Publisher · View at Google Scholar
  8. E. Gomez-Dominguez, J. P. Gisbert, J. A. Moreno-Monteagudo, L. Garcia-Buey, and R. Moreno-Otero, “A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 11, pp. 1643–1647, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Yu, E. S. Chu, S. Wang et al., “Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice,” Gastroenterology, vol. 138, no. 2, pp. 694–704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Foster, M. J. Budo, S. Saab, N. Ahmadi, C. Gordon, and A. D. Guerci, “Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St. Francis heart study randomized clinical trial,” American Journal of Gastroenterology, vol. 106, no. 1, pp. 71–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Yoneda, T. Hasegawa, and K. Sato, “Vitamin E therapy for NAFLD/NASH,” Nutrition, vol. 31, no. 6, pp. 898-899, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Nobili, M. Manco, R. Devito et al., “Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial,” Hepatology, vol. 48, no. 1, pp. 119–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. A. Al-Busafi, M. Bhat, P. Wong, P. Ghali, and M. Deschenes, “Antioxidant therapy in nonalcoholic steatohepatitis,” Hepatitis Research and Treatment, vol. 2012, Article ID 947575, 8 pages, 2012. View at Publisher · View at Google Scholar
  14. G. Musso, R. Gambino, M. Cassader, and G. Pagano, “A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease,” Hepatology, vol. 52, no. 1, pp. 79–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hamaguchi, T. Kojima, Y. Itoh et al., “The severity of ultrasonographic findings in non-alcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation,” American Journal of Gastroenterology, vol. 102, no. 12, pp. 2708–2715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Keles, N. Akar Bayram, T. Kayhan et al., “The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels,” Anadolu Kardiyoloji Dergisi, vol. 8, no. 6, pp. 407–412, 2008. View at Google Scholar
  17. E. S. Ford, U. A. Ajani, and A. H. Mokdad, “The prevalence of high intake of vitamin E from the use of supplements among U.S. adults,” Annals of Internal Medicine, vol. 143, no. 2, pp. 116–120, 2005. View at Publisher · View at Google Scholar
  18. I. M. Hajjar, V. George, E. A. Sasse, and M. S. Kochar, “A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids,” American Journal of Therapeutics, vol. 9, no. 4, pp. 289–293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Goth, “A simple method for determination of serum catalase activity and revision of reference range,” Clinica Chimica Acta, vol. 196, no. 2-3, pp. 143–152, 1991. View at Publisher · View at Google Scholar · View at Scopus
  20. R. A. Lawrence and R. F. Burk, “Glutathione peroxidase activity in selenium deficient rat liver,” Biochemical and Biophysical Research Communications, vol. 71, no. 4, pp. 952–958, 1976. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Racker, “Glutathione reductase from bakers’ yeast and beef liver,” Journal of Biological Chemistry, vol. 217, no. 2, pp. 855–865, 1955. View at Google Scholar
  22. M. P. Murphy, “How mitochondria produce reactive oxygen species,” Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Begriche, A. Igoudjil, D. Pessayre, and B. Fromenty, “Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it,” Mitochondrion, vol. 6, no. 1, pp. 1–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Albano, E. Mottaran, M. Vidali et al., “Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis,” Gut, vol. 54, no. 7, pp. 987–993, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. G. C. Ness, Z. Zhao, and D. Lopez, “Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation,” Archives of Biochemistry and Biophysics, vol. 325, no. 2, pp. 242–248, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. V. G. Athyros, K. Tziomalos, T. D. Gossios et al., “Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis,” The Lancet, vol. 376, no. 9756, pp. 1916–1922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Hyogo, S. Tazuma, K. Arihiro et al., “Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia,” Metabolism, vol. 57, no. 12, pp. 1711–1718, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. M. Nan, W. J. Wu, N. Fu et al., “Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental nonalcoholic steatohepatitis in mice,” Scandinavian Journal of Gastroenterology, vol. 44, no. 9, pp. 1121–1131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. B. Hill, R. Devalarajan, S. Joshi-Barve, S. Barve, and C. J. Mcclain, “Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcohol hepatitis patient monocytes and rat Kupffer cells, in vitro,” Clinical Biochemistry, vol. 32, no. 7, pp. 563–570, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Pignatelli, R. Carnevale, D. Pastori et al., “Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2,” Circulation, vol. 126, no. 1, pp. 92–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Robertson, I. Leclercq, and G. C. Farrell, “Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 281, no. 5, pp. G1135–G1139, 2001. View at Publisher · View at Google Scholar
  32. J. Gutierrez-Correa and O. A. Stoppani, “Inactivation of yeast glutathione reductase by Fenton systems: effect of metal chelators, cateholamines and thiol compounds,” Free Radical Research, vol. 27, no. 6, pp. 543–555, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Garcia-Ruiz and J. C. Fernandez-Checa, “Mitochondrial glutathione: hepatocellular survival-death switch,” Journal of Gastroenterology and Hepatology, vol. 21, no. 3, pp. S3–S6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Letteron, B. Fromenty, B. Terris, C. Degott, and D. Pessayre, “Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice,” Journal of Hepatology, vol. 24, no. 2, pp. 200–208, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino, and A. Terano, “Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 10, pp. 1667–1672, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Kugelmas, D. B. Hill, B. Vivian, L. Marsano, and C. J. Mcclain, “Cytokines and a pilot study of the effects of lifestyle modification and vitamin E,” Hepatology, vol. 38, no. 2, pp. 413–419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. R. S. Strauss, “Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). National Health and Nutrition Examination Survey,” Journal of Pediatrics, vol. 134, no. 2, pp. 160–165, 1999. View at Publisher · View at Google Scholar · View at Scopus